8-K
filed June 9, 2023, 7:59 PM ET
ticker SRPT
CIK 0000873303
other material
confidence high
sentiment negative
materiality 0.60
Sarepta shareholders reject executive compensation in advisory vote; approve equity plan amendments
Sarepta Therapeutics, Inc.
- Advisory vote on 2022 named executive officer compensation failed: 52.8M against vs 20.4M for.
- Approved Amendment No. 3 to 2018 Equity Incentive Plan, increasing authorized shares by 2.5M to 13.2M.
- Approved Amendment No. 2 to ESPP, increasing authorized shares by 300K to 1.4M.
- Re-elected directors Barry, Behrens, Mayo, Nicaise as Class II members for two-year terms.
- Advisory vote on frequency of future executive compensation votes: one year approved with 73M votes.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Sarepta Therapeutics, Inc. shareholders approved Amendment to the Company’s 2018 Equity Incentive Plan at the 2023-06-08 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 3: Amendment to the Company’s 2018 Equity Incentive Plan The stockholders approved the 2018 Plan Amendment. The results of the vote were as follows: For Against Abstain Broker Non-Votes 65,720,789 8,039,982 28,571 8,421,872
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Sarepta Therapeutics, Inc. shareholders approved Advisory Vote on whether an advisory vote on executive compensation should be held every one, two or three years at the 2023-06-08 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 5: Advisory Vote on whether an advisory vote on executive compensation should be held every one, two or three years The stockholders approved, on an advisory basis, the frequency of every one year for an advisory vote on executive compensation. The results of the advisory vote were as follows: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 73,036,748 68,609 617,055 66,930 8,421,872
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Sarepta Therapeutics, Inc. shareholders approved Amendment to the Company’s Amended and Restated 2013 Employee Stock Purchase Plan at the 2023-06-08 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 4: Amendment to the Company’s Amended and Restated 2013 Employee Stock Purchase Plan The stockholders approved the 2016 ESPP Amendment. The results of the vote were as follows: For Against Abstain Broker Non-Votes 73,433,804 332,148 23,390 8,421,872
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Sarepta Therapeutics, Inc. shareholders approved Ratification of KPMG as the Company’s Independent Registered Public Accounting Firm at the 2023-06-08 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 6: Ratification of KPMG as the Company’s Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ended December 31, 2023. The results of the vote were as follows: For Against Abstain 80,401,023 1,747,340 62,851
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Sarepta Therapeutics, Inc. shareholders approved Election of Directors at the 2023-06-08 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company’s board of directors as members of Class II for a term of two years. The results of the vote were as follows: Name of Nominee For Against Abstain Broker Non- Votes Richard J. Barry 53,491,803 20,272,569 24,970 8,421,872 M. Kathleen Behrens, Ph.D. 63,663,186 10,095,019 31,137 8,421,872 Stephen L. Mayo, Ph.D. 69,343,149 4,421,653 24,540 8,421,872 Claude Nicaise, M.D. 61,567,590 12,196,029 25,723 8,421,872
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Sarepta Therapeutics, Inc. shareholders rejected Advisory Vote to Approve Named Executive Officer Compensation at the 2023-06-08 meeting.
- Proposal
- say on pay
- Outcome
- failed
- Meeting
- 2023-06-08
Exact text from the filing
Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders did not approve, on an advisory basis, the compensation of the Company’s named executive officers for 2022. The results of the advisory vote were as follows: For Against Abstain Broker Non-Votes 20,368,530 52,772,697 648,115 8,421,872
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.